Search research articles
Contact Us
Filters
Showing results (501-510 of 537) with videos related to
Page
of 54
Sort By:
Annals of Internal Medicine
|
January 22, 2004
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
Martha Skinner, Vaishali Sanchorawala, David C Seldin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 8, 2019
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body <sup>18</sup>F-Florbetapir PET/CT
Eric C Ehman, M Samir El-Sady, Marie F Kijewski, et al.
JACC. Cardiovascular Imaging
|
August 20, 2018
Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion of Amyloid Deposits
Paco E Bravo, Kana Fujikura, Marie Foley Kijewski, et al.
Circulation. Cardiovascular Imaging
|
November 15, 2022
Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis
Sarah Am Cuddy, Yesh Datar, Gavin Ovsak, et al.
JACC. Heart Failure
|
September 7, 2024
Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes
Olivier F Clerc, Shilpa Vijayakumar, Sarah A M Cuddy, et al.
Cardiovascular Drugs and Therapy
|
February 17, 2020
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Cardiovascular Drugs and Therapy
|
June 18, 2020
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 25, 2023
Prognostic Value of Left Ventricular <sup>18</sup> F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis
Olivier F Clerc, Yesh Datar, Sarah Am Cuddy, et al.
JACC. Cardiovascular Imaging
|
December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy
Sarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
JACC. Cardiovascular Imaging
|
July 13, 2024
Prognostic Value of Left Ventricular <sup>18</sup>F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis
Olivier F Clerc, Yesh Datar, Sarah A M Cuddy, et al.
Page
of 54
Search research articles
Search
Showing results (501-510 of 537) with videos related to
Sort By:
Page
of 54
Annals of Internal Medicine
|
January 22, 2004
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
Martha Skinner, Vaishali Sanchorawala, David C Seldin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 8, 2019
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body <sup>18</sup>F-Florbetapir PET/CT
Eric C Ehman, M Samir El-Sady, Marie F Kijewski, et al.
JACC. Cardiovascular Imaging
|
August 20, 2018
Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion of Amyloid Deposits
Paco E Bravo, Kana Fujikura, Marie Foley Kijewski, et al.
Circulation. Cardiovascular Imaging
|
November 15, 2022
Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis
Sarah Am Cuddy, Yesh Datar, Gavin Ovsak, et al.
JACC. Heart Failure
|
September 7, 2024
Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and Outcomes
Olivier F Clerc, Shilpa Vijayakumar, Sarah A M Cuddy, et al.
Cardiovascular Drugs and Therapy
|
February 17, 2020
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Cardiovascular Drugs and Therapy
|
June 18, 2020
Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Daniel P Judge, Arnt V Kristen, Martha Grogan, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 25, 2023
Prognostic Value of Left Ventricular <sup>18</sup> F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis
Olivier F Clerc, Yesh Datar, Sarah Am Cuddy, et al.
JACC. Cardiovascular Imaging
|
December 19, 2021
Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy
Sarah A M Cuddy, Michael Jerosch-Herold, Rodney H Falk, et al.
JACC. Cardiovascular Imaging
|
July 13, 2024
Prognostic Value of Left Ventricular <sup>18</sup>F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis
Olivier F Clerc, Yesh Datar, Sarah A M Cuddy, et al.
Page
of 54